Baidu
map

强化血糖控制降低糖尿病视网膜病变的风险

2016-06-17 MedSci MedSci原创

ACCORDION研究显示,2型糖尿病患者若控制血糖,则发生糖尿病性视网膜病变的风险减少一半。Emily Chew博士指出,这表明糖尿病患者控制血糖对其眼睛健康及视力有重要作用。 Chew和同事对1310名参与ACCORD研究(2003-2009)的民众进行了调查。参与者被随机分配到实验组和对照组(糖化血红蛋白目标值:<6%:7%、收缩压:<120mmhg:140mmhg、血脂:非诺贝

ACCORDION研究显示,2型糖尿病患者若控制血糖,则发生糖尿病性视网膜病变的风险减少一半。Emily Chew博士指出,这表明糖尿病患者控制血糖对其眼睛健康及视力有重要作用。 


Chew和同事对1310名参与ACCORD研究(2003-2009)的民众进行了调查。参与者被随机分配到实验组和对照组(糖化血红蛋白目标值:<6%:7%、收缩压:<120mmhg:140mmhg、血脂:非诺贝特+辛伐他汀160mg或安慰剂加辛伐他汀)。2010年研究人员检查了参与者的眼睛和眼底情况,2014年对参与者的眼睛和眼底情况进行再次评估(2010-2014)。 

ACCORD研究进行的第8年,研究人员发现,相比血脂对照组,血脂实验组患者出现糖尿病视网膜病变的发生率较低(11.8%:10.2%,调整OR=1.13,95%CI:0.71-1.79)。相比血糖对照组,血糖实验组患者出现糖尿病视网膜病变的发生率较低(5.8%:12.7%,aOR=0.42;95% CI:0.28-0.63)。相比血压对照组,血压实验组患者出现糖尿病视网膜病变的发生率较高(7.5%:6%,aOR=1.21,95%CI:0.61-2.4)。

研究结果提供的证据表明,强化血糖控制有利于减少糖尿病性视网膜病变的进展,2型糖尿病患者尤其明显。并可进一步减少患者发生眼睛、肾脏和神经系统并发症出现的风险。但研究人员表示仍需进一步探究加以证实。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2041974, encodeId=63aa20419e404, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Nov 15 21:14:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126731, encodeId=0f56126e31e5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:50:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269833, encodeId=ca0c126983379, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272927, encodeId=df2012e292781, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413872, encodeId=397914138e218, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2041974, encodeId=63aa20419e404, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Nov 15 21:14:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126731, encodeId=0f56126e31e5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:50:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269833, encodeId=ca0c126983379, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272927, encodeId=df2012e292781, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413872, encodeId=397914138e218, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
    2016-09-14 1e10c84am36(暂无匿称)

    文章不错,值得拜读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2041974, encodeId=63aa20419e404, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Nov 15 21:14:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126731, encodeId=0f56126e31e5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:50:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269833, encodeId=ca0c126983379, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272927, encodeId=df2012e292781, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413872, encodeId=397914138e218, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
    2016-06-19 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=2041974, encodeId=63aa20419e404, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Nov 15 21:14:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126731, encodeId=0f56126e31e5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:50:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269833, encodeId=ca0c126983379, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272927, encodeId=df2012e292781, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413872, encodeId=397914138e218, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2041974, encodeId=63aa20419e404, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue Nov 15 21:14:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126731, encodeId=0f56126e31e5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:50:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269833, encodeId=ca0c126983379, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272927, encodeId=df2012e292781, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413872, encodeId=397914138e218, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jun 19 03:14:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]

相关资讯

JAMA Neurol:儿童卒中后血压、血糖和体温与神经系统预后的关系

根据JAMA Neurology在线发表的一篇文章,儿童卒中后梗塞(组织损伤)体积和高血糖症(高血糖)与较差的神经预后相关,但高血压,发烧与结果无关。儿童患者出现动脉缺血性卒中后,对于能够管理血压,血糖水平和温度的最佳管理没有证据为基础的准则。Lori C. Jordan,范德比尔特大学医学中心范德比尔特大学医学中心的医学博士,和其合作者检测了异常血压,血糖水平的患病率和神经学结果的关系。他们对2

健康笔记丨每个医生都应掌握的临床计算公式

临床常用的这些计算公式,你都知道吗?

Nat Med:糖尿病新药动物实验获成功,一次用药维持4个月,未来有望用于临床

“一次注射药效至少能维持4个月时间。”美国一个研究小组开发出一种控制血糖的新药,并在动物实验中获得成功。研究人员称,该研究涉及一种在人类大脑中天然存在的激素,未来有望为治疗糖尿病提供帮助。相关论文在线发表在《自然—医学》杂志网站上。 Ⅱ型糖尿病是目前最常见的疾病之一,发病率在全球范围呈逐年增高趋势。其特点是血糖病理性升高,如不加以控制极易引发严重的并发症,甚至危及生命。 此前有研究发现,将

米粒大小的气球有望帮助2型糖尿病患者摆脱药物治疗

一个米粒大小的小气球也许会解决英国盛行的糖尿病难题。数十名2型糖尿病患者报名参加实验,希望这一治疗方法能帮助他们摆脱糖尿病药物治疗方案。医生将一端有瘪硅胶气球的细软管经患者咽喉部插入,当细软管的气球端到达十二指肠位置后,通过给气球充气并且通过细软管给气球注入热水的方法消燃烧一部分十二指肠脂肪组织。当气球被充大到能挤压十二指肠时,气球表面的温度会灼伤和消耗肠道周围的脂肪组织,以改善糖尿病患者摄入和吸

盘点:Nature等:外科手术治疗2型糖尿病效果或优于药物和锻炼

图片摘自:www.nature.com/news 本周发表的临床指南阐释了2型糖尿病疗法近一个世纪以来翻天覆地的巨变,该指南提出,涉及对胃部和肠道进行“操作”的手术被认为或许可以作为针对合适候选人的一种标准的疗法;而这也遵循了多项临床试验的研究结果,这些临床试验表明,相比生活方式或药物干预而言,胃肠道手术可更加有效地改善患者机体的血糖水平,而且会使得患者机体的症状得到长期缓解。 20世

Nature :添加人工甜味剂的饮料可能有害人体健康

曾经有一段时光,美国洛克菲勒大学分子生物学家Thomas Huber每天喝36盎司健怡可乐(diet cola)。一年多之前,作为Thomas P. Sakmar教授化学生物学与信号转导实验室的一名助理教授,Huber对添加人工调味剂的饮料如何可能影响他的身体对糖的加工能力感到好奇。他决定在他自己身上开展实验。苏打水中添加有阿斯巴甜(aspartame),其中阿斯巴甜是美国FDA批准的一种人工

Baidu
map
Baidu
map
Baidu
map